Bio-Works Technologies AB (BIOWKS) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Bio-Works Technologies AB SEK 0.40, price SEK 3.17, upside -87.4%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Bio-Works Technologies AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range kr 0.7900 – kr 28.60 · fair‑value band kr 0.2635 – kr 0.5015 · the kr 3.17 price screens above the kr 0.3995 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Bio-Works Technologies in your weekly email
Every Wednesday you see whether Bio-Works Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Bio-Works Technologies AB (publ), together with its subsidiaries, engages in the manufactures and sale of chromatography resins for the purification of biopharmaceuticals in Sweden.
Show more
Bio-Works Technologies AB (publ), together with its subsidiaries, engages in the manufactures and sale of chromatography resins for the purification of biopharmaceuticals in Sweden. The company offers affinity and activated resin, hydrophobic interaction chromatography (HIC) resins, GoBio Mini and GoBio prepacked columns, ion exchange chromatography (IEX) resin, immobilized metal-ion affinity chromatography (IMAC) resin, size exclusion chromatography (SEC) resins, HTPD formats, screening kits, and desalting columns; and WorkBeads chromatography resins. Its products are used in antibodies, his-tagged proteins, proteins, peptides, oligonucleotides, and viruses and vaccines applications. Bio-Works Technologies AB (publ) founded in 2006 and is headquartered in Uppsala, Sweden.
Stock analysis
Bio-Works Technologies AB (BIOWKS) currently trades at kr 3.17, while our model-based Fair Value estimate is kr 0.3995, implying the stock looks roughly 693.7% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: kr 0.2635 (bear) to kr 0.5015 (bull), the price of kr 3.17 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Bio-Works Technologies AB reported revenue of 62.5M SEK in FY2025 versus 21.9M SEK in FY2021, a compound +30.0%/yr. Reported net income was −15.2M SEK in FY2025.
Key figures
Market cap 345M SEK (≈ $34.8M) · P/S ratio 4.16 · EPS (TTM) kr −0.0300 · Net margin −24.4% · Return on equity −5.7% · Return on assets (EBIT) −49.4% · Operating margin 12.6% · Revenue (TTM) 82.8M SEK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 32% below its 52-week high and 43% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −87%, BIOWKS screens richer than that median.
Fair Value models
Bear kr 0.2635Fair Value kr 0.3995Bull kr 0.5015
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+145.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+53.9%
Start year 2020 (pandemic). Over 10 years: +44.8% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+44.8%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−631.1% (2020) → −28.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Bio-Works Technologies AB with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 203 stocks
Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside−87% · Bottom 25%
Profitability
Return on assets−6% · Bottom 25%
Net margin (TTM)−3% · Bottom 25%
Operating margin (TTM)13% · Above median
Growth and dividend
Revenue growth227% · Top 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/B0.71× · Cheapest 25%
P/S (TTM)0.42× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 18
FUTURE (revenue growth)100· sector 31
PAST (return on equity)0· sector 25
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 33
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Bio-Works Technologies AB Fair Value". https://www.fairvalue-calculator.com/stock/BIOWKS
Frequently asked questions
Is Bio-Works Technologies AB (BIOWKS) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 0.3995 versus a price of kr 3.17, about −87% upside (overvalued).
What is the fair value of BIOWKS?
Our model-based fair value for Bio-Works Technologies AB is kr 0.3995 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 3.17.
What is the quality score of BIOWKS?
Bio-Works Technologies AB has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bio-Works Technologies AB (BIOWKS)?
Our model-based price target is the fair value of kr 0.3995 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario kr 0.2635, optimistic scenario kr 0.5015. It is a calculation from audited fundamentals, not an analyst target.
What is the Bio-Works Technologies AB stock forecast for 2026?
Our models put fair value at kr 0.3995, about −87% upside versus a price of kr 3.17 (overvalued). Cautious scenario kr 0.2635, optimistic scenario kr 0.5015. The calculation is refreshed regularly with new filings.
What is the revenue of Bio-Works Technologies AB (BIOWKS)?
Bio-Works Technologies AB reported trailing-twelve-month revenue of about 82.8M SEK (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Bio-Works Technologies AB (BIOWKS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bio-Works Technologies AB it is kr 0.3995 per share (as of Sep 24, 2026), against a price of kr 3.17. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Bio-Works Technologies AB stock overvalued or undervalued in 2026?
As of Sep 24, 2026, BIOWKS trades above its calculated fair value: price kr 3.17, fair value kr 0.3995, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BIOWKS?
No. The price is what the market pays today (kr 3.17); the fair value is what the company's own numbers justify (kr 0.3995). For Bio-Works Technologies AB the two are kr 2.77 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bio-Works Technologies AB worth?
The market values Bio-Works Technologies AB at about 345M SEK (market capitalisation, as of Sep 24, 2026). Per share that is kr 3.17; our models calculate a fair value of kr 0.3995 per share.
What do the bullish and bearish scenarios say about BIOWKS?
Our models span a range for Bio-Works Technologies AB: cautious scenario kr 0.2635, base kr 0.3995, optimistic kr 0.5015 per share (as of Sep 24, 2026, price kr 3.17). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Bio-Works Technologies AB (BIOWKS)?
Balance-sheet figures for Bio-Works Technologies AB (as of Sep 24, 2026): return on equity −5.7%. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is BIOWKS from its 52-week high?
Bio-Works Technologies AB trades at kr 3.17, about 32% below its 52-week high of kr 4.68 and 43% above the low of kr 2.21 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.3995 is for.
Which stocks are comparable to Bio-Works Technologies AB?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bio-Works Technologies AB stock attractive at the current price?
The data as of Sep 24, 2026: price kr 3.17, calculated fair value kr 0.3995 (−87%), Quality Score 52/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BIOWKS calculated?
We run Bio-Works Technologies AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.3995, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Bio-Works Technologies AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bio-Works Technologies AB (BIOWKS)?
The closing price on Sep 24, 2026 was kr 3.17. Our model-based fair value is kr 0.3995, about −87% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bio-Works Technologies AB right now?
The price sits above even our optimistic bull case (kr 0.5015). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (kr 0.2635 to kr 0.5015) leaves room in how you read the outcome.
Key figures of Bio-Works Technologies AB
How large is the market capitalisation of Bio-Works Technologies AB (BIOWKS)?
The market capitalisation of Bio-Works Technologies AB is 345M SEK (≈ $34.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bio-Works Technologies AB (BIOWKS)?
The price-to-sales ratio of Bio-Works Technologies AB is 4.16 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bio-Works Technologies AB (BIOWKS)?
Earnings per share at Bio-Works Technologies AB are kr −0.0300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Bio-Works Technologies AB (BIOWKS)?
The net margin of Bio-Works Technologies AB is −24.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bio-Works Technologies AB (BIOWKS)?
The return on equity (ROE) of Bio-Works Technologies AB is −5.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bio-Works Technologies AB (BIOWKS)?
On an EBIT basis the return on assets of Bio-Works Technologies AB is −49.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bio-Works Technologies AB (BIOWKS)?
The operating margin of Bio-Works Technologies AB is 12.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bio-Works Technologies AB (BIOWKS)?
Revenue at Bio-Works Technologies AB is growing +227% versus a year earlier (3y avg +14.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Bio-Works Technologies AB (BIOWKS) generate?
The free cash flow of Bio-Works Technologies AB is −19.2M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Bio-Works Technologies AB (BIOWKS) hold?
Bio-Works Technologies AB holds more cash than debt, 34.9M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Bio-Works Technologies AB in the live analysis
One click puts Bio-Works Technologies AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
